Prognostic significance of Pgp, MRP1, and MRP3 in ovarian cancer patients

Authors: I. Sedláková 1;  J. Laco 2;  J. Tošner 1;  J. Špaček 1
Authors‘ workplace: Porodnická a gynekologická klinika LF UK a FN, Hradec Králové, přednosta doc. MUDr. J. Špaček, PhD., IFEPAG 1;  Fingerlandův ústav patologie LF UK a FN, Hradec Králové, přednosta prof. MUDr. A. Ryška, Ph. D. 2
Published in: Ceska Gynekol 2015; 80(6): 405-413


To evaluate the correlation of resistance proteins Pgp (P-glycoprotein), MRP1 (Multidrug Related Protein, Multidrug Resistance–Associated Protein) and MRP3 with clinical – pathological factors and to find the clinical outcome of these data in ovarian cancer patients.

Prospective study.

Department of Gynecology and Obstetrics, Charles University in Prague, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové.

133 patients with epithelial ovarian cancer who underwent primary surgery from 2006–2010 had specimens stained with imunohistochemistry for Pgp, MRP1, MRP3.

The histological subtype of epithelial ovarian cancer correlated with the expression of PgP, MRP1, and MRP3. The lowest incidence of Pgp and MRP1 expression was documented in endometrioid ovarian cancers (P = 0.151, P = 0.013). Patients with advanced ovarian cancer (FIGO III+IV) had higher MRP1 expression than those with early stage ovarian cancer (Med MRP1 FIGO I+II 80%; CI: 60–100; FIGO III+IV 100%; CI: 90–100; P = 0.100). An association was observed between MRP1 and tumor grade (Med MRP1 G1 80% (CI: 0–100), G2 80% (CI: 30–100), G3 100% (CI: 90–100); P < 0.001). There was no relationship between the size of the residual tumor after primary surgery and any resistance proteins. Patients with complete response after primary treatment had lower levels of LRP, Pgp, and MRP1 expression than other patients. Patients with higher Pgp and MRP1 expression had relapse of disease during the following 24 months more often than patients with lower Pgp and MRP1 expression. FIGO stage, histological type, debulking efficiency, and Pgp and MRP1 expression correlated with poor patient survival (P < 0.001, P < 0.001, P < 0.001, P = 0.040, P = 0.026).

We found prognostic significance of Pgp, MRP1 and MRP3 expression in ovarian cancer patients. MRP1 have some additional prognostic value for the clinical outcome of patients with ovarian carcinoma.

ovarian carcinoma, Pgp/ABCB1, MRP1/ABCC1, MRP3/ABCC3, drug resistance


1. Arao, S., Suwa, H., Mandai, M., et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res, 1995, 54, p. 1355–1359.

2. Arts, HJ., Katsaros, D., de Vries, FG., et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res, 1999, 5, p. 2798–2805.

3. Borst, P., Evers, P., Kool, M., Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst, 2000, 92, p. 1295–1302.

4. Cibula, D., Petruželka, L., a kol. Onkogynekologieedition. Praha, Grada Publishing, 2009.

5. Fruehauf, PJ., Alberts, DS. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol, 2005, 23, p. 3641–3643.

6. Glavinas, H., Krajcsi, P., Cserepes, J., et al. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv, 2004, 1, p. 27.

7. Goff, AB., Paley, JP., Greer, EB., Grown, MA. Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol Oncol, 2001, 81, p. 18–24.

8. Gottesman, MM., Fojo, T., Bates, SE. Multidrug resistance in cancer: role of ATP-dependent transporters. NatRevCancer, 2002, 2, p. 48–58.

9. Holzmayer, TA., Hilsenbeck, S., Von Hoff DD., Roninson, IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst, 1992, 84, p. 1486–1491.

10. Charpin, C., Vielh, P., Duffaud, F., et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst, 1994, 86, p. 1539–1545.

11. Ikeda, K., Sakai, K., Yamamoti, R., et al. Multivariate analysis for prognostic significance of histologic sybtype, GST-pi, MDR-1, and p-53 in stages II-IV ovarian cancer. Int J Gynecol Cancer, 2003, 13, p. 776–784.

12. Izquierdo, MA., van der Zee, AG., Vermorken, JB., et al. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst, 1995, 87, p. 1230–1237.

13. Kurman, JR., Shih, M. The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory. Am J Surg Pathol, 2010, 34, p. 1–18.

14. Kuwano, M., Uchiumi, T., Hayakawa, H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 and angiogenesis-related factors in human malignancies. Cancer Sci, 2003, 94, p. 9–14.

15. Materna, V., Pleger, J., Hoffmann, U., Lage, H. RNA-expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol, 2004, 94, p. 152–160.

16. Nosková, V., Hajdúch, M., Mihál, V., Cwiertka, K. Mechanismy mnohočetné lékové rezistence a jejich význam pro klinickou praxi. Klinická onkologie, 2000, 13, s. 4–9.

17. Scheffer, GL., Wijngaard, PL., Flens, MJ., et al. The drug resistance related protein LRP is the human major vault protein. Nat Med, 1995, 1, p. 578–582.

18. Schinkel, AH. P-Glycoprotein, a gatekeeper in the blood-brain barier. Adv Drug Deliv Rev, 1999, 36, s. 179–194.

19. Václavíková, R., Hubáčková, M., Kubala, E., et al. Exprese genu mnohočetné lékové rezistence 1 (MDR1) a její význam v rozvoji a terapii karcinomu prsu. Klinická onkologie, 2007, 3, s. 253–259.

20. Yakirevich, E., Sabo, E., Naroditsky, I., et al. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol, 2006, 100, p. 152–159.

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account